Please login to the form below

Not currently logged in
Email:
Password:

TEVA-48125

This page shows the latest TEVA-48125 news and features for those working in and with pharma, biotech and healthcare.

Teva says chronic migraine drug is ready for phase III

Teva says chronic migraine drug is ready for phase III

Teva says chronic migraine drug is ready for phase III. TEV-48125 efficacy “ has not previously been achieved”. ... Teva's novel migraine drug TEV-48125 should start phase III trials shortly, after showing 'unprecedented' activity in a mid-stage study

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics